Quintiles agrees to buy Advion BioServices
Creates a one-source solution for lab testing
Quintiles has agreed to acquire Advion BioServices, a US bioanalytical laboratory, to provide a more comprehensive and efficient global solution for laboratory customers, for an undisclosed sum.
Advion BioServices provides Good Laboratory Practice (GLP) pharmacokinetic/pharmacodynamic (PK/PD) testing and other services.
‘Adding a premier bioanalytical offering to our existing CAP-accredited central labs network creates a one-source solution for lab testing across the development spectrum, anywhere in the world,’ said Thomas Wollman, senior vp, Quintiles Global Laboratories.
Tom Kurz, Advion BioServices’ president and co-founder, said: ‘This transaction is good for Advion, Quintiles and our pharmaceutical and biotherapeutics customers, who will benefit from enhanced efficiency of Advion and Quintiles coupling bioanalytical testing with global sample management, central labs, and clinical trials management.’
Advion BioServices employs more than 180 people in three US locations. Co-founders Kurz and Jack Henion, as well as other members of the management team will remain involved with the renamed Advion Bioanalytical Labs within Quintiles.